These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16451396)

  • 1. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
    Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
    Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.
    Brugiatelli M; Federico M; Gobbi PG; Avanzini P; Callea V; Cavanna L; De Pasquale A; Di Prisco AU; Di Rienzo N; Silingardi V
    Haematologica; 1993; 78(5):306-12. PubMed ID: 8314160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
    Merli F; Bertini M; Luminari S; Mozzana R; Bertè R; Trottini M; Stelitano C; Botto B; Pizzuti M; Quintana G; De Paoli A; Federico M;
    Haematologica; 2004 Aug; 89(8):973-8. PubMed ID: 15339681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Longo G; Fiorani C; Sacchi S; Callea V; Lombardo M; Federico M; Stelitano C; Angrilli F; Vallisa D; Gobbi PG; Ilariucci F; Frassoldati A; Petrini M; Silingardi V
    Haematologica; 1999 May; 84(5):425-30. PubMed ID: 10329921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital.
    Bai LY; Yang MH; Chiou TJ; Liu JH; Yen CC; Wang WS; Hsiao LT; Chao TC; Chen PM
    Cancer; 2003 Sep; 98(6):1188-95. PubMed ID: 12973842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.